Serum seeks DGCI approval to use Covovax Vaccine as a booster

Serum Institute Demands Regulatory Approval for Booster Dose: Serum Institute of India (SII) has sought DCGI’s nod to market its COVID-19 vaccine – Covax – as a booster dose for people above the age of 18 years. According to official sources, SII has sought approval for the vaccine to be given to adults who have been given two doses of Covishield or Covaxin. Covax is an indigenous version of a covid vaccine developed by Novovax Inc. and manufactured under license from Serum Institute of India.

COVOVAX was approved by WHO in December 2021

Covovax is the indigenous version of the Covid vaccine. It has been developed by Novovax Inc. Serum has produced it. This is a type of protein vaccine that produces immunity in the body. In December 2021, Covovax was recognized by the WHO as a booster dose. WHO had said that it is like a boon for low-income countries. This vaccine of serum is effective in fighting against all the viruses of Kovid in emergency. Adar Poonawalla, director of Serum, had said that it is our achievement that WHO has recognized Covovax.

Adar Poonawala tweeted and told the milestone

Terming it as a milestone, Adar Poonawalla, CEO, Serum Institute of India said, “This is another milestone in our fight against COVID-19. Covovax is now for emergency use WHO has allowed it to be used in emergency. This booster dose is showing excellent safety and effectiveness to avoid Kovid. Thank you all for a great cooperation. Let us tell you that SII also manufactures Covishield vaccine which has been widely rolled out in the Indian vaccination campaign.

Know how COVOVAX works?

Covovax activates the immunity cells after entering the body. Its nano particles do this work very well. With their activation, the body’s B cells start releasing antibodies. When a real virus attacks the body, they start doing their work.